

10th April 2023

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Cipla signs perpetual licensing agreement with Novartis Pharma AG for Galvus® range for diabetes therapy in India

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that Cipla Limited has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) on 10th April 2023 to manufacture and market Galvus® and Galvus® combination brands, used in the treatment of type 2 diabetes from 1st January 2026. The agreement is subject to satisfaction of certain conditions precedent. During the interim period we would continue to market and distribute Galvus® branded products.

Galvus® is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category. Galvus® has the potential to contribute significantly to Cipla's portfolio in the diabetes care continuum space with reported sales of INR 268 Cr (IQVIA MAT February 2023).

This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category.

This is for your information and records.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode